<DOC>
	<DOCNO>NCT00702806</DOCNO>
	<brief_summary>The primary objective trial investigate appropriate dose single injection Org 36286 initiate multifollicular growth first seven day control ovarian hyperstimulation ( COH ) protocol IVF IVF/ICSI . After seven day , participant convert treatment Puregon® 150 IU administration GnRH antagonist Orgalutran® finalize stimulation cycle . Secondary objective safety ( include absence antibody formation ) direct effect Org 36286 reproductive function ( steroidogenesis , oocyte maturation , embryo quality implantation ) .</brief_summary>
	<brief_title>Investigate Dose Org 36286 Initiate Multiple Follicular Growth Controlled Ovarian Hyperstimulation Protocol IVF IVF/ICSI ( P07015 )</brief_title>
	<detailed_description>This trial make two stage different design conduct two clinical trial site . Stage I open-label uncontrolled small cohort woman ( n=6 ) obtain first experience employ Org 36286 woman meet inclusion none exclusion criterion . Based result previous study , appropriate dose anticipate 120 μg Org 36286 , administer Cycle Day 2 3 . After seven day , treatment continue fix dose 150 IU Puregon® SC . If size lead follicle &gt; =14 mm , 0.25 mg Orgalutran® SC daily administer concurrently 150 IU Puregon® include day hCG . The maximum total treatment duration 19 day . Treatment first two participant Org 36286 120 μg , expect adequate COH , cancel due disrupt follicular growth beyond Day 7 . Therefore , dose Org 36286 adapt 120 μg 180 µg . Treatment first participant give indication validity anticipate dos use Stage II , actual dose-finding trial . Stage II open-label , prospective randomize , compare three experimental regimen differ dose Org 36286 ( 120 μg , 180 μg , 240 μg ) reference treatment . Post-treatment assessment complete visit two week embryo transfer .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Females couple indication COH IVF IVF/ICSI ; Body mass index ( BMI ) &gt; =18 &lt; =29 kg/m^2 ; Normal menstrual cycle length : 2435 day ; Ejaculatory sperm ; History of/or current endocrine abnormality polycystic ovary syndrome ( PCOS ) , polycystic ovary accord ultrasound scan ( USS ) , ( treat ) hyperprolactinemia evidence ovarian dysfunction ; More three unsuccessful COH cycle IVF since last establish ongoing pregnancy ( applicable ) ; History non low ovarian response FSH/human menopausal gonadotropin ( hMG ) treatment ; Any clinically relevant hormone value outside reference range early follicular phase ( menstrual Cycle Day 27 ) measure local laboratory ( FSH , luteinizing hormone [ LH ] , estradiol [ E2 ] , progesterone [ P ] , total testosterone [ T ] , thyroid stimulate hormone [ TSH ] , prolactin ) ; Any clinically relevant abnormal laboratory value ; Any ovarian and/or abdominal abnormality interfere ultrasound examination ; Contraindications use gonadotropin ( e.g . tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) ; Epilepsy , diabetes , cardiovascular , gastrointestinal , hepatic , renal , pulmonary , abdominal disease ; History presence alcohol drug abuse within 12 month prior sign informed consent ; Hypersensitivity Orgalutran® component ; Administration investigational drug within three month prior screen . Use hormonal preparation within one month prior start Org 36286 exception thyroid medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pharmacological effect drug</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormone substitute Hormone Antagonists</keyword>
	<keyword>Pharmacological Actions</keyword>
	<keyword>Randomized</keyword>
	<keyword>Multi-center</keyword>
	<keyword>Multi-national</keyword>
</DOC>